Pre-Hour Spike In Longevity Health (XAGE) Stock Driven By Merger Confidence

During today’s pre-market session, Longevity Health Holdings, Inc. (NASDAQ: XAGE) shares jumped 35.95% to $4.16. This notable gain in stock value followed a key regulatory event related to the company’s proposed merger with 20/20 BioLabs, Inc. With a positive ruling from the Nasdaq Hearings Panel, XAGE is permitted to continue listing on The Nasdaq Stock Market, provided that the combined company satisfies the original listing requirements by September 2, 2025.

Strategic Roadmap Endorsement

Following a careful analysis of Longevity Health’s strategic strategy, including its financial disclosures and merger ambitions, the Nasdaq panel rendered its decision. Shortly after submitting the S-4 registration statement for the transaction on May 8, 2025, XAGE executed a 1-for-30 reverse stock split on May 12, 2025, in order to comply with Nasdaq regulations. By giving the business a significant exemption, the Panel’s ruling gives it more time to complete the merger and prove that it fully complies with listing requirements.

Merger Momentum and Product Launch Plans

With regulatory clearance in hand, Longevity Health is now intensifying efforts to complete the merger with 20/20 BioLabs. Post-merger, the combined company plans to introduce a medicated cleanser targeted for use in physicians’ offices and MedSpas. This product will be cross-promoted to 20/20 BioLabs’ customer network, which primarily includes firefighters.

Conversely, 20/20 BioLabs is preparing to release a diagnostic lab test designed to detect inflammatory biomarkers associated with premature aging and skin disorders. This new offering will be marketed to Longevity Health’s established network of healthcare providers and MedSpa professionals.

New Partnerships Expand Market Reach

In parallel with the merger, 20/20 BioLabs has embarked on a retail initiative with Giant Food, piloting its OneTest multi-cancer screening product at nine stores in Maryland and Virginia. The supermarket chain is also thinking about expanding the partnership to include biomarker testing for items that cause inflammation, which might generate more income for the combined company.

These accomplishments highlight a pivotal period of change for 20/20 BioLabs and Longevity Health (XAGE), with strategic synergies poised to redefine their combined market presence.